Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02617589 : An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)
PhasePhase 3
AgesMin: 18 Years Max: N/A
Eligibility
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Males and Females, age ? 18 years old

- Newly-diagnosed brain cancer or tumor called glioblastoma or GBM

- Tumor test result shows MGMT unmethylated type

- Karnofsky performance status of ? 70 (able to care for self)

Exclusion Criteria:

- Prior treatment for GBM (other than surgical resection)

- Any known tumor outside of the brain

- Recurrent or secondary GBM

- Active known or suspected autoimmune disease

- Biopsy with less than 20% of tumor removed
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02617589      |      Link to official Clinicaltrials.gov listing
Locations
Liverpool, New South Wales
Australia

Facility: Local Institution
Investigator:
Contact: Site 0002
Email not avaialable

St. Leonards, New South Wales
Australia

Facility: Royal North Shore Hospital
Investigator:
Contact: Mustafa Khasraw, Site 0005 Phone: +61294631373
Email not avaialable

Heidelberg, Victoria
Australia

Facility: Local Institution
Investigator:
Contact: Site 0003
Email not avaialable

Prahran, Victoria
Australia

Facility: Local Institution
Investigator:
Contact: Site 0004
Email not avaialable

Nedlands, Western Australia
Australia

Facility: Sir Charles Gairdner Hospital
Investigator:
Contact: Anna Nowak, Site 0001 Phone: +61408818656
Email not avaialable

Linz,
Austria

Facility: Kepler Universitaetsklinikum
Investigator:
Contact: Josef Pichler, Site 0061
Email not avaialable

Vienna,
Austria

Facility: Medical University Of Vienna
Investigator:
Contact: Matthias Preusser, Site 0060
Email not avaialable

Vancouver, British Columbia
Canada

Facility: British Columbia Cancer Agency-Vancouver Ctr
Investigator:
Contact: Brian Thiessen, Site 0014 Phone: 6048776000
Email not avaialable

Toronto, Ontario
Canada

Facility: Princess Margaret Cancer Centre
Investigator:
Contact: Warren Mason, Site 0035 Phone: 4165817823
Email not avaialable

Montreal, Quebec
Canada

Facility: Montreal Neurological Institute and Hospital
Investigator:
Contact: Kevin Petrecca, Site 0074 Phone: 5143982801
Email not avaialable

Bonn,
Germany

Facility: Universitaetsklinikum Bonn
Investigator:
Contact: Ulrich Herrlinger, Site 0051 Phone: +4922828719887
Email not avaialable

Erlangen,
Germany

Facility: Uniklinik Erlangen
Investigator:
Contact: Martin Uhl, Site 0072 Phone: +4991318534640
Email not avaialable

Frankfurt am Main,
Germany

Facility: Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main
Investigator:
Contact: Oliver Baehr, Site 0049 Phone: +4969630187711
Email not avaialable

Freiburg,
Germany

Facility: Medizinische Universitaetsklinik Freiburg
Investigator:
Contact: Oliver Schnell, Site 0073 Phone: +4976127050010
Email not avaialable

Hamburg,
Germany

Facility: Universitaetsklinikum Hamburg
Investigator:
Contact: Manfred Westphal, Site 0054 Phone: +4940741035316
Email not avaialable

Heidelberg,
Germany

Facility: Universitaetsklinik Heidelberg
Investigator:
Contact: Antje Wick, Site 0052 Phone: +4962215638265
Email not avaialable

Koeln,
Germany

Facility: Universitaetsklinik Koeln
Investigator:
Contact: Norbert Galldiks, Site 0139 Phone: +492214784015
Email not avaialable

Muenster,
Germany

Facility: Universitaetsklinikum Muenster
Investigator:
Contact: Oliver Grauer, Site 0050
Email not avaialable

Munich,
Germany

Facility: Klinikum rechts der Isar der Technischen Universitat Munchen
Investigator:
Contact: Stephanie Combs, Site 0138
Email not avaialable

Regensburg,
Germany

Facility: Bezirksklinikum Regensburg
Investigator:
Contact: Peter Hau, Site 0055 Phone: +499419413290
Email not avaialable

Tuebingen,
Germany

Facility: Universitasklinikum Tubingen
Investigator:
Contact: Ghazaleh Tabatabai, Site 0056
Email not avaialable

Petach Tikva,
Israel

Facility: Local Institution
Investigator:
Contact: Site 0096
Email not avaialable

Tel Aviv,
Israel

Facility: Local Institution
Investigator:
Contact: Site 0097
Email not avaialable

Bologna,
Italy

Facility: Local Institution
Investigator:
Contact: Site 0076
Email not avaialable

Milano,
Italy

Facility: Local Institution
Investigator:
Contact: Site 0079
Email not avaialable

Padova,
Italy

Facility: Local Institution
Investigator:
Contact: Site 0126
Email not avaialable

Rozzano (milano),
Italy

Facility: Local Institution
Investigator:
Contact: Site 0135
Email not avaialable

Siena,
Italy

Facility: Local Institution
Investigator:
Contact: Site 0078
Email not avaialable

Torino,
Italy

Facility: Azienda Ospedaliera Citta della Salute e della Scienza
Investigator:
Contact: Roberta Ruda, Site 0077
Email not avaialable

Tokyo,
Japan

Facility: Local Institution
Investigator:
Contact: Site 0112
Email not avaialable

Nagoya-shi, Aichi
Japan

Facility: Local Institution
Investigator:
Contact: Site 0115
Email not avaialable

Chiba-shi, Chiba
Japan

Facility: Local Institution
Investigator:
Contact: Site 0125
Email not avaialable

Hiroshima-Shi, Hiroshima
Japan

Facility: Local Institution
Investigator:
Contact: Site 0123
Email not avaialable

Sapporo-shi, Hokkaido
Japan

Facility: Local Institution
Investigator:
Contact: Site 0122
Email not avaialable

Kobe, Hyogo
Japan

Facility: Local Institution
Investigator:
Contact: Site 0129
Email not avaialable

Tsukuba-shi, Ibaraki
Japan

Facility: Local Institution
Investigator:
Contact: Site 0111
Email not avaialable

Kanazawa-shi, Ishikawa
Japan

Facility: Local Institution
Investigator:
Contact: Site 0121
Email not avaialable

Kagoshima-shi, Kagoshima
Japan

Facility: Local Institution
Investigator:
Contact: Site 0131
Email not avaialable

Sagamihara-shi, Kanagawa
Japan

Facility: Local Institution
Investigator:
Contact: Site 0133
Email not avaialable

Kumamoto-shi, Kumamoto
Japan

Facility: Local Institution
Investigator:
Contact: Site 0119
Email not avaialable

Kyoto-shi, Kyoto
Japan

Facility: Local Institution
Investigator:
Contact: Site 0117
Email not avaialable

Kyoto-shi, Kyoto
Japan

Facility: Local Institution
Investigator:
Contact: Site 0116
Email not avaialable

Okayama-shi, Okayama
Japan

Facility: Local Institution
Investigator:
Contact: Site 0134
Email not avaialable

Hirakata-shi, Osaka
Japan

Facility: Local Institution
Investigator:
Contact: Site 0120
Email not avaialable

Suita-shi, Osaka
Japan

Facility: Local Institution
Investigator:
Contact: Site 0130
Email not avaialable

Hidaka-shi, Saitama
Japan

Facility: Local Institution
Investigator:
Contact: Site 0113
Email not avaialable

Bunkyo-ku, Tokyo
Japan

Facility: Local Institution
Investigator:
Contact: Site 0128
Email not avaialable

Chuo-ku, Tokyo
Japan

Facility: Local Institution
Investigator:
Contact: Site 0114
Email not avaialable

Mitaka-shi, Tokyo
Japan

Facility: Local Institution
Investigator:
Contact: Site 0118
Email not avaialable

Yamagata-shi, Yamagata
Japan

Facility: Local Institution
Investigator:
Contact: Site 0110
Email not avaialable

Warszawa,
Poland

Facility: Local Institution
Investigator:
Contact: Site 0081
Email not avaialable

Moscow,
Russian Federation

Facility: Local Institution
Investigator:
Contact: Site 0105
Email not avaialable

Badalona-Barcelona,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0027
Email not avaialable

Barcelona,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0030
Email not avaialable

Barcelona,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0028
Email not avaialable

Madrid,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0029
Email not avaialable

Madrid,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0031
Email not avaialable

Santiago De Compostela,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0026
Email not avaialable

Valencia,
Spain

Facility: Local Institution
Investigator:
Contact: Site 0025
Email not avaialable

Geneve,
Switzerland

Facility: University Hospital Geneva
Investigator:
Contact: Pierre-Yves Dietrich, Site 0059
Email not avaialable

Lausanne,
Switzerland

Facility: Centre hospitalier universitaire Vaudois (CHUV)
Investigator:
Contact: Andreas Hottinger, Site 0057
Email not avaialable

Zuerich,
Switzerland

Facility: Universitaetsspital Zuerich
Investigator:
Contact: Patrick Roth, Site 0053 Phone: +41442551111
Email not avaialable




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740